Panama

The primary regulatory authority for health products in Panama is the Direccion Nacional de Farmacia y Drogas (DNFD), operating under the Ministerio de Salud (MINSA). The principal governing legislation is Law 1 of 2001 and its implementing regulations, which establish the legal framework for the registration, control, and surveillance of pharmaceuticals, medical devices, diagnostics, and related health products. All health products intended for commercialization in Panama must obtain a Registro Sanitario (sanitary registration) prior to market entry. The DNFD evaluates applications through a technical review process that assesses safety, efficacy, and quality, with expedited pathways available for products previously approved by recognized reference agencies such as the US FDA, EMA, or Health Canada.

Applicants must appoint a locally registered legal representative or distributor authorized to act on behalf of the manufacturer in Panama, and all documentation must be submitted in Spanish or accompanied by certified translations. Panama generally accepts dossiers structured according to the Common Technical Document (CTD) format, and regulators give significant weight to prior approvals from stringent regulatory authorities as part of an abbreviated review pathway. Panama is a member of the Red Panamericana para la Armonizacion de la Reglamentacion Farmaceutica (PANDRH) network, which supports regional harmonization efforts. In recent years, MINSA has undertaken modernization initiatives to digitize submission processes and reduce administrative backlogs, including the implementation of an online registry platform, though procedural timelines can still vary considerably depending on product class and dossier completeness.

Public procurement of health products in Panama is managed through a centralized government structure anchored by MINSA and the Caja de Seguro Social (CSS), the national social security system, which together represent the dominant buyers of health products in the public sector. The CSS operates with significant institutional autonomy and runs its own procurement processes to supply its hospital and clinic network, which covers a large portion of the formally employed population. Public tenders are governed by Law 22 of 2006 on public contracting and are administered through the government procurement portal Panama Compra, which mandates transparency and open competition for most acquisitions above defined thresholds. The Hospital Santo Tomas and other public health facilities may also conduct independent procurement for specific needs, though large-volume purchases are typically coordinated centrally.

The private health sector in Panama is well-developed, particularly in Panama City, and operates through direct commercial channels involving distributors, wholesalers, and private hospital group purchasing. Panama does not currently benefit from large-scale donor-funded procurement programs such as those managed by the Global Fund, USAID, or Gavi to the extent seen in lower-income countries in the region, given its upper-middle-income status. However, Panama participates in the Pan American Health Organization (PAHO) Strategic Fund, which allows public entities to access competitively priced essential medicines and health supplies through a pooled procurement mechanism. There are no formal local manufacturing preference policies that systematically advantage domestically produced products in public tenders, though local distributors play a critical role as intermediaries and their relationships with procurement offices can influence commercial outcomes.